fenfluramine
E874310
Fenfluramine is a medication repurposed from its former use as an appetite suppressant to serve as an anti-seizure drug, particularly effective in reducing seizures in patients with Dravet syndrome.
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
anorectic agent
ⓘ
antiepileptic drug ⓘ fluoroamphetamine derivative ⓘ medication ⓘ serotonergic agent ⓘ |
| hasAdverseEffect |
decreased appetite
ⓘ
diarrhea ⓘ fatigue ⓘ pulmonary arterial hypertension ⓘ somnolence ⓘ valvular heart disease ⓘ |
| hasATCCode |
A08AA01
ⓘ
N03AX29 ⓘ |
| hasBioavailability | high oral bioavailability ⓘ |
| hasBrandName | Fintepla NERFINISHED ⓘ |
| hasCASNumber | 458-24-2 ⓘ |
| hasChemicalFormula | C12H16F3N ⓘ |
| hasContraindication |
concomitant use with monoamine oxidase inhibitors
ⓘ
history of valvular heart disease ⓘ pulmonary arterial hypertension ⓘ |
| hasCurrentMarketingAuthorizationHolder | UCB Pharma NERFINISHED ⓘ |
| hasDeveloper | Zogenix NERFINISHED ⓘ |
| hasDrugInteraction |
MAO inhibitors
NERFINISHED
ⓘ
SSRIs NERFINISHED ⓘ serotonergic drugs ⓘ triptans ⓘ |
| hasFormerIndication | obesity ⓘ |
| hasHalfLife | approximately 20 hours ⓘ |
| hasIUPACName | N-ethyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine ⓘ |
| hasLegalStatus | prescription only ⓘ |
| hasMechanismOfAction |
positive modulator of sigma-1 receptor
ⓘ
serotonin releasing agent ⓘ serotonin reuptake inhibitor ⓘ |
| hasMetabolite | norfenfluramine ⓘ |
| hasMolarMass | 231.26 g/mol ⓘ |
| hasRegulatoryApprovalFor |
treatment of Dravet syndrome in children
ⓘ
treatment of Lennox–Gastaut syndrome in patients aged 2 years and older ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| hasStereochemistry | racemic mixture ⓘ |
| hasTherapeuticUse |
treatment of Dravet syndrome
ⓘ
treatment of Lennox–Gastaut syndrome ⓘ treatment of seizures ⓘ |
| isAdministeredAs | oral solution ⓘ |
| isExcretedBy | kidney ⓘ |
| isMetabolizedBy | liver ⓘ |
| mayCause | serotonin syndrome ⓘ |
| requiresMonitoring | echocardiogram ⓘ |
| wasRepurposedFrom | appetite suppressant ⓘ |
| wasWithdrawnAsAppetiteSuppressant | due to risk of cardiac valvulopathy ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.